ERBB2 and breast cancer: Radioimmunotherapy (RIT) for HER2+ BC has been developed, mainly with trastuzumab and therapeutic radionuclides, mainly the β-emitters 131 I, 177Lu, and 188Re; 111In (as Auger electron emitter); and the α-emitters 225Ac, 227 Th, and 212Pb.